[go: up one dir, main page]

MA51582B1 - Exon skipping oligomer conjugates for muscular dystrophy - Google Patents

Exon skipping oligomer conjugates for muscular dystrophy

Info

Publication number
MA51582B1
MA51582B1 MA51582A MA51582A MA51582B1 MA 51582 B1 MA51582 B1 MA 51582B1 MA 51582 A MA51582 A MA 51582A MA 51582 A MA51582 A MA 51582A MA 51582 B1 MA51582 B1 MA 51582B1
Authority
MA
Morocco
Prior art keywords
oligomer conjugates
muscular dystrophy
exon skipping
skipping oligomer
exon
Prior art date
Application number
MA51582A
Other languages
French (fr)
Other versions
MA51582A (en
Inventor
Marco Passini
Gunnar Hanson
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066509 external-priority patent/WO2018118662A1/en
Publication of MA51582A publication Critical patent/MA51582A/en
Publication of MA51582B1 publication Critical patent/MA51582B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des conjugués oligomère antisens capables de se lier à un site cible sélectionné du gène de la dystrophine humaine pour induire le saut de l'exon 53 sont décrites.Antisense oligomer conjugates capable of binding to a selected target site of the human dystrophin gene to induce skipping of exon 53 are described.

MA51582A 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy MA51582B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436223P 2016-12-19 2016-12-19
PCT/US2017/066509 WO2018118662A1 (en) 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy

Publications (2)

Publication Number Publication Date
MA51582A MA51582A (en) 2019-10-23
MA51582B1 true MA51582B1 (en) 2022-10-31

Family

ID=65895705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51582A MA51582B1 (en) 2016-12-19 2017-12-14 Exon skipping oligomer conjugates for muscular dystrophy

Country Status (2)

Country Link
AR (1) AR110390A1 (en)
MA (1) MA51582B1 (en)

Also Published As

Publication number Publication date
AR110390A1 (en) 2019-03-27
MA51582A (en) 2019-10-23

Similar Documents

Publication Publication Date Title
MA65895B1 (en) EXON SKIPPING-INDUCING OLIGOMERIC CONJUGATES FOR MUSCULAR DYSTROPHY
MA45618A (en) OLIGOMERIC EXON BREAKS FOR MUSCLE DYSTROPHY
EA201991450A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
MX2019006882A (en) Exon skipping oligomer conjugates for muscular dystrophy.
CY1121876T1 (en) EXON BYPASS COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
MY205772A (en) Exon skipping oligomer conjugates for muscular dystrophy
IL268856A (en) Methods for the purification of messenger RNA
IL271389A (en) Non-viral DNA proceeds are intended
CY1123119T1 (en) ANTI-SENSE NUCLEIC ACID
EP3463290A4 (en) HIV-1 REACTION CONTROL BY GENETIC EDITION STRATEGY
EA201891317A2 (en) THERAPEUTIC TARGETS FOR CORRECTION OF HUMAN DISTROPHIN GENE BY EDITING GENES AND METHODS OF THEIR APPLICATION
WO2019241385A3 (en) Exon skipping oligomers for muscular dystropy
EA202092772A1 (en) OLIGOMER CONJUGATES FOR EXONE PASSING IN MUSCLE DYSTROPHY
EP3347466A4 (en) DETERMINING THE NUMBER OF GENETIC COPIES USING SMASH NUCLEOTIDE HIGH SPEED MULTIPLEX SEQUENCING
EP3673505A4 (en) INJECTION KIT FOR EPITAXIAL DEPOSIT PROCESSES
EP3367784A4 (en) ORGAN ENGINEERING HUMANIZED BY GENETIC COMPLETION
EA202191601A1 (en) OLIGOMER CONJUGATES FOR EXON SKIP IN MUSCULAR DYSTROPHY
EP3693487A4 (en) AUSTENITE BASED STAINLESS STEEL
MA51582B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
MA51587B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
MA47015B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
EP3363464A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER COMPRISING AN RNA OLIGONUCLEOTIDE
EP3311164A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF APPENDICITY AND DIFFERENTIATION OF CAUSES OF ABDOMINAL PAIN
FR3033489B3 (en) GUIDE FOR THE POSITIONING OF ORTHODONTIC ATTACHES
EP3397267A4 (en) PEPTIDES FOR THE TREATMENT OF BONE RESORPTION DISEASE